Monthly Archives: April 2018

Genprex Expands Operations to Cambridge, Mass

CAMBRIDGE, MA / ACCESSWIRE / April 25, 2018 / Genprex, Inc.(NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has established offices in Cambridge, Mass.

Read More

Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences

AUSTIN, Texas, April 18, 2018 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that it has entered an agreement with The University of Texas at Austin Dell Medical School

Read More

Genprex Provides Clinical and Corporate Update

AUSTIN, Texas, April 16, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, today announced a clinical and corporate update.

Read More

Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy

AUSTIN, Texas and CAMBRIDGE, Mass., April 11, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Julien L. Pham, MD, MPH as the Company's President.

Read More

Genprex to Present at The MicroCap Conference

AUSTIN, Texas, April 6, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that Rodney Varner, Chairman and CEO, will present at The MicroCap Conference

Read More

Genprex Announces Closing of Initial Public Offering

AUSTIN, Texas, April 4, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the closing of its initial public offering on April 3, 2018 of an aggregate of 1,280,000 shares of common stock at a public offering price

Read More